Mangoceuticals, Inc. Announces Registered Direct Offering and Concurrent Private Placement

On December 18, 2025, Mangoceuticals, Inc. entered into a securities purchase agreement with an institutional investor for a registered direct offering and a concurrent private placement. The offering includes the sale of 1,430,502 shares of common stock at $1.295 per share and 500,000 pre-funded warrants at $1.29499 per warrant. Additionally, common stock purchase warrants exercisable for up to 1,930,502 shares of common stock were issued in a private placement at an exercise price of $1.4245 per share. The aggregate gross proceeds from these transactions are approximately $2.5 million. The company also entered into a placement agency agreement with Aegis Capital Corp., paying a 7% fee and reimbursing expenses. A registration rights agreement was signed, requiring the company to file a resale registration statement within 30 days. The net proceeds will be used for working capital and general corporate purposes. The company also announced the pricing of the offering via press release.